RxDoctor Payments Data

Atoussa Farough, MD

Internal Medicine · Woodbridge, VANPI 1902063720

Payments from drug & device makers

$6,726in general payments, 2019–2025

Across 268 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$2K
  • Novo Nordisk$1K
  • AbbVie$683
  • Lilly USA, LLC$643
  • AstraZeneca$462
  • GSK$273
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,236100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,726 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$164,010
Medicare patients
347
Services billed
2,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$115,594
EliquisApixaban28$44,445
FarxigaDapagliflozin Propanediol30$34,104
JanuviaSitagliptin Phosphate28$33,559
JardianceEmpagliflozin21$30,536
TrulicityDulaglutide14$30,100
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,962
XareltoRivaroxaban11$9,373
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$8,053
Varenicline Tartrate14$5,735
Rosuvastatin Calcium308$4,169
Novolog FlexpenInsulin Aspart14$2,437
Levothyroxine Sodium234$2,292
Wixela InhubFluticasone Propion/Salmeterol26$2,082
Atorvastatin Calcium242$2,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,070$115,59474 claims
PfizerEliquis$193$44,44528 claims
AstraZenecaFarxiga$462$34,10430 claims
MerckJanuvia$173$33,55928 claims
Boehringer IngelheimJardiance$80$30,53621 claims
Lilly USA, LLCTrulicity$643$30,10014 claims
GSKTrelegy Ellipta$273$17,96224 claims
Johnson & JohnsonXarelto$28$9,37311 claims
AbbVieSynthroid$683$1,99226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Woodbridge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →